213 related articles for article (PubMed ID: 27216562)
1. Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest.
Zhao Y; Tu MJ; Wang WP; Qiu JX; Yu AX; Yu AM
Sci Rep; 2016 May; 6():26611. PubMed ID: 27216562
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth.
Zhao Y; Tu MJ; Yu YF; Wang WP; Chen QX; Qiu JX; Yu AX; Yu AM
Biochem Pharmacol; 2015 Dec; 98(4):602-13. PubMed ID: 26518752
[TBL] [Abstract][Full Text] [Related]
3. A genetically engineered microRNA-34a prodrug demonstrates anti-tumor activity in a canine model of osteosarcoma.
Alegre F; Ormonde AR; Snider KM; Woolard K; Yu AM; Wittenburg LA
PLoS One; 2018; 13(12):e0209941. PubMed ID: 30596759
[TBL] [Abstract][Full Text] [Related]
4. Long Noncoding RNA SNHG7 Promotes the Tumor Growth and Epithelial-to-Mesenchymal Transition via Regulation of miR-34a Signals in Osteosarcoma.
Deng Y; Zhao F; Zhang Z; Sun F; Wang M
Cancer Biother Radiopharm; 2018 Nov; 33(9):365-372. PubMed ID: 29989838
[TBL] [Abstract][Full Text] [Related]
5. The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.
Pu Y; Zhao F; Li Y; Cui M; Wang H; Meng X; Cai S
BMC Cancer; 2017 Jan; 17(1):45. PubMed ID: 28073349
[TBL] [Abstract][Full Text] [Related]
6. The Optimal Outcome of Suppressing Ewing Sarcoma Growth
Li DF; Yuan Y; Tu MJ; Hu X; Li YZ; Yi WR; Li PC; Zhao Y; Cheng Z; Yu AM; Jian C; Yu AX
Front Oncol; 2020; 10():222. PubMed ID: 32161722
[TBL] [Abstract][Full Text] [Related]
7. Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization.
Wang WP; Ho PY; Chen QX; Addepalli B; Limbach PA; Li MM; Wu WJ; Jilek JL; Qiu JX; Zhang HJ; Li T; Wun T; White RD; Lam KS; Yu AM
J Pharmacol Exp Ther; 2015 Aug; 354(2):131-41. PubMed ID: 26022002
[TBL] [Abstract][Full Text] [Related]
8. p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression.
Novello C; Pazzaglia L; Conti A; Quattrini I; Pollino S; Perego P; Picci P; Benassi MS
PLoS One; 2014; 9(12):e114757. PubMed ID: 25490093
[TBL] [Abstract][Full Text] [Related]
9. Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.
Tu MJ; Ho PY; Zhang QY; Jian C; Qiu JX; Kim EJ; Bold RJ; Gonzalez FJ; Bi H; Yu AM
Cancer Lett; 2019 Feb; 442():82-90. PubMed ID: 30389433
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-34a inhibits tumor invasion and metastasis in osteosarcoma partly by effecting C-IAP2 and Bcl-2.
Wen J; Zhao YK; Liu Y; Zhao JF
Tumour Biol; 2017 Jun; 39(6):1010428317705761. PubMed ID: 28635396
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-661 Enhances TRAIL or STS Induced Osteosarcoma Cell Apoptosis by Modulating the Expression of Cytochrome c1.
Fan L; Zhu C; Qiu R; Zan P; Zheng Z; Xu T; Li G
Cell Physiol Biochem; 2017; 41(5):1935-1946. PubMed ID: 28391262
[TBL] [Abstract][Full Text] [Related]
12. MiR-34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene.
Pu Y; Zhao F; Wang H; Cai S
Sci Rep; 2017 Mar; 7():44218. PubMed ID: 28281638
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of microRNA-496 suppresses proliferation, invasion, migration and in vivo tumorigenicity of human osteosarcoma cells by targeting eIF4E.
Qi NN; Tian S; Li X; Wang FL; Liu B
Biochimie; 2019 Aug; 163():1-11. PubMed ID: 30998968
[TBL] [Abstract][Full Text] [Related]
14. The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis.
Vetter NS; Kolb EA; Mills CC; Sampson VB
Mol Cancer Res; 2017 Jul; 15(7):953-964. PubMed ID: 28275089
[TBL] [Abstract][Full Text] [Related]
15. Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models.
Jian C; Tu MJ; Ho PY; Duan Z; Zhang Q; Qiu JX; DeVere White RW; Wun T; Lara PN; Lam KS; Yu AX; Yu AM
Oncotarget; 2017 May; 8(19):30742-30755. PubMed ID: 28415566
[TBL] [Abstract][Full Text] [Related]
16. Clinical case report of patients with osteosarcoma and anticancer benefit of calycosin against human osteosarcoma cells.
Qiu R; Ma G; Li X; Shi Q; Li X; Zhou X; Tang Y; Xie Z; Liao S; Qin Y; Wang R; Ye Y; Luo J; Zhang J
J Cell Biochem; 2019 Jun; 120(6):10697-10706. PubMed ID: 30652346
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-145 inhibits tumour growth and metastasis in osteosarcoma by targeting cyclin-dependent kinase, CDK6.
Li Y; Liu J; Liu ZZ; Wei WB
Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5117-5125. PubMed ID: 28051259
[TBL] [Abstract][Full Text] [Related]
18. miR-363 acts as a tumor suppressor in osteosarcoma cells by inhibiting PDZD2.
He F; Fang L; Yin Q
Oncol Rep; 2019 May; 41(5):2729-2738. PubMed ID: 30896877
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether à go-go 1 expression.
Wu X; Zhong D; Gao Q; Zhai W; Ding Z; Wu J
Int J Med Sci; 2013; 10(6):676-82. PubMed ID: 23569431
[TBL] [Abstract][Full Text] [Related]
20. MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines.
Fenger JM; Roberts RD; Iwenofu OH; Bear MD; Zhang X; Couto JI; Modiano JF; Kisseberth WC; London CA
BMC Cancer; 2016 Oct; 16(1):784. PubMed ID: 27724924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
